You have less caloric fuel
In a randomized placebo-controlled, double-blinded trial, although liraglutide did not affect A load and cognition measures, 26 weeks of liraglutide treatment prevented expected decline of glucose metabolism that signifies cognitive impairment, synaptic dysfunction, and disease evolution (243)
Our drug discovery and development division, Calibr-Skaggs, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare
The drug received approval from the European Medicines Agency (EMA) in 2023 and later gained FDA approval in August 2024, becoming the first FDA-approved treatment for adult hypoparathyroidism
DPP4i reduces long-term cardiovascular risk after percutaneous coronary intervention in patients with diabetes via the insulin-like growth factor-1 axis [77]
